In a report published Thursday, Jefferies analyst Raj Denhoy reiterated a Buy rating on DexCom DXCM, and raised the price target from $21.00 to $27.00.
In the report, Jefferies noted, “DXCM put up a strong 2Q with product revenues +65% on uptake of G4 and guidance was raised by $10mm. G4 demand is proving durable suggesting growth will stay good for some time to come. Stay at Buy, PT to $27.”
DexCom closed on Wednesday at $21.98.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
